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Abstract 
 
Cell-cell contacts coordinate the endothelial barrier function in response to external 
cues. To identify new mediators involved in cytokine-promoted endothelial 
permeability, we screened a siRNA library targeting E3 ubiquitin ligases. Here, we 
report that silencing of the late endosome/lysosomal membrane-associated RING-CH-3 
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(MARCH3) enzyme protects the endothelial barrier. Furthermore, transcriptome 
analysis unmasked the upregulation of the tight junction-encoding gene occludin 
(OCLN) in MARCH3-depleted cells. Indeed, MARCH3 silencing results in the 
strengthening of cell-cell contacts, as evidenced by the accumulation of junctional 
proteins. From a molecular standpoint, the FoxO1 forkhead transcription repressor was 
inactivated in the absence of MARCH3. This provides a possible molecular link between 
MARCH3 and the signaling pathway involved in regulating the expression of junctional 
proteins and barrier integrity. 
 
Introduction 
The vascular endothelium forms a semi-permeable selective barrier that allows the 
controlled passage of fluids, molecules and cells to and from the bloodstream. This 
function relies on the organization of cell-cell junctions, orchestrated notably through 
VE-cadherin-based adherens junctions (AJs) [1,2]. Angiogenic and inflammatory factors 
elevate endothelial permeability and operate through various signaling pathways; this 
can involve both transcriptional control of VE-cadherin and post-translational 
modifications of AJ-enriched proteins, such as phosphorylation of VE-cadherin and its 
partners, VE-cadherin internalization and cytoskeleton contractility [1,3-8]. Of note, VE-
cadherin expression and trafficking control AJ organization, as well as composition of 
tight junctions (TJs) and vice versa [9,10]. Indeed, claudin-5-dependent TJs are not 
functional in VE-cadherin (CDH5)-null endothelial cells [9,11]. From a molecular 
standpoint, VE-cadherin sustains the activation of the PI-3 kinase (PI3K)/AKT pathway, 
and the subsequent phosphorylation of the forkhead repressor transcription factor 
FoxO1, leading to its inhibition [9,11]. Conversely, in cells lacking VE-cadherin, non-
phosphorylated active FoxO1 accumulated within the nucleus where CLDN5 gene 
expression is constitutively silenced. Consequently, this effect was lost upon rescue of 
VE-cadherin expression. Modulation of the FoxO1 pathway might thus coordinate the 
composition of AJs and TJs in endothelial cells, while involved in vascular homeostasis 
and endothelial proliferation [9,11-13]. 
Besides phosphorylation, ubiquitylation can also take part in trafficking and 
degradation of adhesion molecules, as envisioned by early reports on cadherin 
internalization [14,15]. Proteasome-mediated degradation was indeed proposed to 
coordinate VE-cadherin stability and therefore AJ architecture and endothelial barrier 
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integrity [4,15]. For instance, internalized VE-cadherin could be processed through a 
lysosomal/proteasome pathway [15-17]. More recently, inflammatory agents, such as 
bradykinin and histamine, were established to provoke VE-cadherin ubiquitylation in 
vitro and in vivo [4]. This process was suggested to be required for VE-cadherin 
internalization and vascular barrier opening. Interestingly, blood-brain barrier damage 
was shown to be associated with occludin ubiquitylation and degradation [18]. 
Furthermore, the viral transmembrane ubiquitin ligase K5 encoded by the Kaposi 
Sarcoma Herpes Virus, which displays some homologies with the MARCH E3 ubiquitin 
ligase family, was shown to down-regulate membrane availability of host targets such 
as CD31/PECAM, VE-cadherin and α, β, γ-catenins, and therefore impacts on endothelial 
cell-cell remodeling and barrier function [19,20]. 
Although lysosomal trafficking and ubiquitylation of endothelial junctional proteins 
appear intertwined, the ubiquitin ligases involved in theses processes are yet to be 
characterized. Here, we inferred that endosome/lysosome resident E3 ubiquitin ligases 
might contribute to endothelial barrier permeability. Therefore, we deployed a siRNA 
library screen that targets transmembrane E3 ubiquitin ligases and identified MARCH3 
as a regulator of endothelial permeability in response to inflammatory factors. 
 
Results  
A siRNA library screen identifies the E3 ubiquitin ligase MARCH3 in the 
endothelial barrier function.  
To identify transmembrane E3 ubiquitin ligases potentially interfering with cytokine-
induced permeability, human umbilical vein endothelial cells (HUVECs) were 
transfected with siRNA duplexes against 46 E3 ubiquitin ligases (2 sequences/target, 
[21]) or with non-silencing RNA (sic, 4 sequences) [21]. Cells were seeded on semi-
porous collagen-coated membranes for permeability assays [3,22]. When knocked 
down, none of the tested E3 ubiquitin ligases further exacerbated IL-8- and histamine-
promoted permeability (Table S1). Conversely, the silencing of nine of them (namely 
BFAR, MARCH2, MARCH3, MARCH6, RNF122, RNF133, RNF152, RNF175, and TRIM59) 
was sufficient to quell IL-8-induced permeability (Fig. 1A, left panel, green and yellow 
dots). Amongst these hits, MARCH3, RNF152 and TRIM59 were shared in the histamine-
triggered permeability screen (Table S1, Fig. 1A, right panel, green and yellow dots). 
Based on the literature, we further focused on MARCH3 (Fig. 1A, green dots), as it has 
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been previously linked to the endocytosis and trafficking of plasma membrane proteins 
[23,24]. The silencing of MARCH3 in human endothelial cells led to a significant 
reduction in both IL-8- and histamine-promoted permeability by around 40%, while 
sparing non stimulated cells (Fig. 1A-B, Table S1). To further validate MARCH3 as a 
negative regulator of endothelial integrity, the permeability of human endothelial cell 
monolayers was next challenged using independent siRNA sequences (Fig. 1C), whose 
efficiency was evaluated through RT-PCR to around 60% of extinction for the most 
robust one (Fig. 1C). Of note, the transcript levels of MARCH2, one of the closest 
homologue of MARCH3 remained unaltered (Fig. 1C). In these conditions, MARCH3 
silencing impaired the permeability increases in both macrovascular (HUVECs, [25]) 
and microvascular (hCMEC/D3, [26,27]) endothelial cells (Fig. 1D-E). Thus, our data 
identified MARCH3 as a lysosomal component involved in cytokine-provoked 
endothelial permeability elevation. 
MARCH3-silenced endothelial cells exhibited strengthened cell-cell junctions. 
Because of the prominent role of cell-cell contacts in orchestrating the endothelial 
barrier function [3,4,8,9], we next explored whether MARCH3 silencing impacts on 
endothelial junctional organization. Interestingly, neither cell viability nor cell density 
was affected by MARCH3 depletion (Fig. 2A-B). Furthermore, confocal analysis of three-
days old endothelial monolayers revealed that IL-8 induced an overall reorganization of 
phalloidin-labeled cell borders (Fig. 2C-D). However, the chemokine failed to do so in 
MARCH3-depleted endothelial cells (Fig. 2C-D), suggesting again that the reduction of 
MARCH3 expression levels opposed to IL-8, provoked junctional remodeling and 
subsequent increases in endothelial permeability. In keeping with this idea, 
immunofluorescence staining on three-days old monolayers unveiled a discrete but 
significant increase in VE-cadherin staining intensity at the borders of adjacent cells 
(Fig. 2E). This was corroborated by an augmentation in surface-exposed VE-cadherin, as 
evaluated by flow cytometry (Fig. 2F). Thus, our data support the idea that endothelial 
adherens junctions are strengthened in MARCH3-silenced cells. 
Tight junctions are strengthened in MARCH3-depleted cells.  
To further explore the mechanisms by which MARCH3 depletion prevents permeability 
increases, we next conducted a gene array analysis. The transcriptome of non-silencing 
control RNA-transfected human brain endothelial cells (sic) was compared to the one of 
MARCH3 siRNA-transfected cells. This unbiased transcriptomic analysis identified few 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
protein encoding RNA (67% of total modified sequences) that were consistently up- 
(49%) or down-regulated (51%) in MARCH3-depleted cells (Table S2, Fig. 3A-C). 
Among the up-regulated genes was OCLN, which encodes the TJ protein occludin (Table 
S2, Fig. 3A-C). Indeed, RT-PCR analysis confirmed that the siRNA-mediated down-
regulation of MARCH3 was accompanied with an augmentation of OCLN transcription 
(Fig. 3C-D). Furthermore, CLDN5 messengers were also elevated, while CDH5 gene 
expression was only slightly enhanced (Fig. 3D). In agreement with this, the levels of 
occludin and claudin-5 TJ proteins were strongly augmented in the absence of MARCH3 
(Fig. 3E). Once again, VE-cadherin expression was only mildly affected, suggesting that 
unlike occludin and claudin-5, the effect of MARCH3 depletion on VE-cadherin 
expression is likely indirect and might rather reflect a positive feedback loop, ignited 
through TJ stabilization (Fig. 2E-F) [9]. At the level of junctional organization, this 
results in reinforced TJ organization, as illustrated by augmented ZO-1 recruitment at 
cell borders (Fig. 3F). Thus, MARCH3 silencing, which prevents permeability increases, 
drives the up-regulation of TJ protein expression that may ultimately culminate in the 
strengthening of endothelial cell-cell junctions.  
MARCH3 impact on OCLN gene expression relies on the FoxO pathway.  
The forkhead transcription repressor factor FoxO1 controls claudin-5 protein 
expression [9,13], and was more recently found involved in vascular remodeling [12]. 
Remarkably, MARCH3 depletion in three-days old starved endothelial cell monolayers 
was sufficient to enhance the phosphorylation of AKT and FoxO1/3, a signature for the 
inhibition of this transcription factor (Fig. 4A). In line with this, FoxO1 nuclear 
accumulation was reduced upon MARCH3 silencing, as examined by 
immunofluorescence-based confocal analysis (Fig. 4B). We next investigated whether 
the effect of MARCH3 silencing on occludin expression was mediated through FoxO1 
activity. To this end, endothelial cells were challenged with the well-characterized 
FoxO1 inhibitor AS1708727 [28]. Interestingly, we found that FoxO1 inhibitor 
treatment was sufficient to elevate OCLN expression, while leaving intact MARCH3 
mRNA levels (Fig. 4C). Moreover, pharmacological blockade of FoxO1 blunted 
histamine- and IL-8-induced permeability (Fig. 4D). As FoxO1 inhibition phenocopied 
MARCH3 depletion, it may act through the inhibition of the transcriptional repression 
activity of FoxO1, as previously demonstrated in the context of the CLDN5 promoter [9]. 
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Collectively, our data favor a model in which MARCH3 sustains the basal activation of 
FoxO1 that counterpoises barrier reinforcement. 
 
Discussion 
In conclusion, our data show that the late endosome/lysosome-anchored MARCH3 E3 
ligase controls the expression of the TJ proteins, occludin and claudin-5, most likely via 
its impact on the transcriptional repressor FoxO. Meanwhile, the overall cell-cell 
junctions appeared reinforced and VE-cadherin expression affected, although to a lesser 
extent. We thus unmasked MARCH3 as a novel regulator of the endothelial barrier, as its 
silencing allows endothelial cells to resist to cytokine-triggered cortical actin 
remodeling and permeability increase. From a molecular standpoint, our results are 
reminiscent of the signaling pathway operating downstream of AJ and regulating 
claudin-5 expression, where FoxO plays an instrumental role in steady state and/or 
recovery of the endothelial barrier integrity [9,13]. Indeed, MARCH3 silencing causes 
up-regulation of both claudin-5 and occludin expression, which in turn might 
strengthen TJ architecture. 
Further studies are required to identify MARCH3 molecular targets, as well as the type 
of ubiquitin modifications involved. Nevertheless, our study highlights the potential 
importance of ubiquitin ligases, particularly deubiquitylating enzymes, in modulating 
the composition of the endothelial junctions. Of note, it has been recently reported that 
occludin can be regulated by ubiquitin-targeted degradation [18,29] during the course 
of permeability increase. Interestingly, at least two different lysine residues on claudin 
have been reported to serve as ubiquitin chain acceptors [30,31]. This raised the 
possibility that MARCH3 might directly or indirectly modulate the 
ubiquitination/degradation status of tight junction protein complexes and requires 
further investigation. 
In addition, the E3 ubiquitin ligase RNF152, which was found in our initial screen (Table 
S1), was recently acknowledged to direct the ubiquitylation of the RagA GTPase in 
response to amino acid starvation and thus to modulate mTORC1 lysosomal signaling 
[32]. Although we did not pursue on RNF152 in our study, it may be interesting to 
investigate the possible synergy between RNF152 and MARCH3 in regards to mTORC1 
and lysosomal signaling in endothelial homeostasis and barrier integrity. There is now 
growing evidence that mTORC1 contributes to endothelial homeostasis [33], while 
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FoxO1 emerged as an instrumental mediator of vascular remodeling operating at the 
interface between metabolic activity and quiescence/proliferation balance [12]. 
In conclusion, MARCH3 might sustain the basal activation of FoxO1, which can then be 
modulated to ensure a rapid and adaptive response of the endothelium. A better 
knowledge on the basic mechanisms involved in integrating microenvironmental cues 
and fundamental signaling pathways might improve our understanding of vascular 
dysfunctions, including exacerbated permeability that occurs in many diseases and 
human pathologies. 
 
 
Materials and Methods 
Cell culture and transfections 
Human umbilical vein endothelial cells (Eahy926 HUVECs) were purchased from ATCC 
and maintained in DMEM plus 10% fetal bovine serum (Life Technologies). Human 
cerebral microvascular endothelial cells (hCMEC/D3, [27]) were grown on collagen-
coated plates in EBM2 complete medium (Lonza). Cells were transfected using 
Lipofectamine RNAimax (Life Technologies) according to the manufacturer’s 
instructions. Non-silencing (Med GC) and MARCH3-targetting Stealth siRNA were from 
Life Technologies (#1 5’-UGGAGGAUUGUGGCAGCCUAGUGAA, #2 5’-
CGGGCAGCUGCUGUCAACAGUAGUG, #3 5’-AGGCCGUUAGUGGAGUGGCUGAGAA). The E3 
ubiquitin ligase-targeting siRNA Mission library was designed with Sigma [21]. 
Permeability assays 
Permeability assays were performed as described previously in [25,27]. Briefly, 105 
transfected HUVECs and 5.105 hCMEC/D3 cells were seeded onto collagen-coated 3.0 
and 0.4 μm pore size PTFE membrane inserts (Corning), respectively. The passage of 
FITC-labeled 40kDa dextran (Life Technologies) was measured 30 min after IL-8 (50 
ng/ml) or histamine (100 mM) challenge using a BMG Labtech automate plate reader. 
Screening on IL-8 and histamine-treated cells was conducted as described previously 
[27]. The library consists of 4 non-silencing sequences (sic) and 2 sequences per target 
[21]. Non-treated cells were included for the 4 sic-transfected conditions only, to serve 
as internal controls for histamine and IL-8 action. 
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Reagents and Antibodies 
FoxO1 inhibitor AS1708727 was from Merck and used at 100 nM. Primary antibodies 
used were: VE-cadherin, GAPDH, and tubulin (Santa Cruz), occludin and claudin-5 (Life 
Technologies), p-FoxO1, p-FoxO1/3, p-AKT, and AKT (Cell Signaling). Primary 
antibodies were diluted at 1/1000 for western-blots. HRP-coupled antibodies were 
from Jackson Immunoresearch (1/5000 dilution). 
Immunofluorescence 
Samples for immunofluorescence were processed as described in [34]. Briefly, samples 
were fixed in paraformaldhedyde 4%, permeabilized in Triton 0.5% and blocked in PBS-
BSA 3%. Primary antibodies were goat anti-VE-cadherin (1/200 dilution, Santa Cruz), 
rabbit anti-FoxO1/3 (1/100 dilution, Cell Signaling) and mouse anti-ZO1 (1/200 
dilution, BD transduction laboratories). Secondary antibodies were from Life 
Technologies (AlexaFluor488 conjugated, 1/500 dilution). Actin cytoskeleton was 
stained using Alexa488-conjugated phalloidin (1/1000 dilution, Life Technologies). 
Samples were processed in parallel, mounted in DAPI-containing fluoromount (Life 
Technologies) and imaged using similar settings on confocal microscope (Nikon A1 Rsi, 
Micropicell, Nantes, France). Images were prepared with Image J software and blinded 
post-analysis performed by two independent individuals. 
Flow Cytometry 
Cells were gently scratched and processed for flow cytometry as described in [34]. 
Briefly, cells were incubated at 4°C with IgG2a PE-conjugated anti-VE-cadherin 
antibodies and control immunoglobulins (R&D). 10.000 events were gated on an Accuri 
C6 cytometer (BD Biosciences) and analyzed using FlowJo. 
Western-Blots and RT-PCR 
Total cell lysates were prepared and processed for western-blots as described in [34]. 
Membranes were imaged using the Fusion FX7 chemiluminescence system (Vilber). RT-
PCR were conducted as described in [34]. 
Transcriptome analysis 
The expression profile of human brain endothelial cells, either control or MARCH3-
depleted (two days post-transfection) was performed with the HG-U133 Plus 2.0 
Affymetrix GeneChip arrays (Genomic’ Platform, Institute Cochin, Paris, France). 
Supervised clustering analysis of these microarrays was then conducted using p value > 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
0.05 and fold change + 1.2. A final list of 513 genes was found down- or up-regulated 
(Table S2). 
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Figure Legends 
 
Figure 1. A siRNA library screen identifies the E3 ubiquitin ligase MARCH3 in the 
endothelial barrier function. 
(A) HUVECs were transfected with two siRNA sequences targeting 46 transmembrane-
anchored E3 ubiquitin ligases (Table S1, [21]) or non-silencing control duplexes RNA 
(sic) and plated onto collagen-coated inserts. Three days later, monolayers were 
starved overnight prior 30 min stimulation with either IL-8 (50 ng/ml) or histamine 
(100 mM). Sic-transfected untreated and treated cells were used as internal controls. 
FITC-dextran permeability was expressed as percentage of inhibition with respect to 
sic-transfected treated cells (% of siRNA control). Hits were considered, when 
permeability was reduced by a third (yellow dots). MARCH3 is shown in green. (B) 
HUVECs were transfected with either non-silencing duplexes (sic) or MARCH3-targeting 
siRNA (siM3, from the library panel A). Permeability was assessed upon IL-8 and 
histamine challenge three days later. (C) HUVECs were transfected with three different 
siRNA sequences targeting MARCH3 (siM3). Knockdown efficiency was assessed by RT-
PCR and quantitative densitometry represented as percentage of inhibition (% inh.).. 
Scans are representative of two independent experiments. (D-E) FITC-dextran 
permeability was measured in similarly treated sic- and siM3-transfected HUVECs (D) 
and brain endothelial cells hCMEC/D3 (E). Values were expressed as a fold to untreated 
sic-transfected cells (ctl). Red/blue columns were compared to the black ones. In 
addition, p<0.001 and p<0.01 for black columns compared to the white ones in (D) and 
(E), respectively. All panels are representative of at least three independent 
experiments, except when specified. ANOVA test and T-test *, p<0.05; **, p<0.01. 
 
Figure 2. MARCH3-silenced endothelial cells exhibited strengthened cell-cell 
junctions. 
(A-F) HUVECs were transfected with siM3 or sic and harvested three days later. (A) 
Viability was measured by MTT in complete medium. Graph shows the mean optical 
densities (OD, as indicated). (B) Cell density was assessed by the ratio between cell-
covered area/total culture areas by Image J software (Fiji). (C) The organization of cell-
cell contact was estimated with phalloidin staining at cell borders. Cells engaged with at 
least 4 neighboring cells and exhibiting at least two ‘zigzag’ patterns at cell-cell contacts 
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were counted as positive. (D) Confocal analysis of cortical actin organization through 
phalloidin staining in cells that were left untreated (control) or challenged with IL-8 (30 
min, 50 ng/ml). Higher magnifications are shown to depict cell-cell contacts. Scale bars: 
10 µm. (E-F) Confocal analysis (E) and flow cytometry analysis (F) of cell surface VE-
cadherin (VE-cad) in sic- or siM3-transfected cells. Scale bars: 10 µm. Graph shows ratio 
of pixel intensities between sic/siM3 conditions from 5 random pictures in 3 
independent experiments. All panels are representative of at least three independent 
experiments, except when specified. T-test *, p<0.05; **, p<0.01. 
 
Figure 3. Tight junctions are strengthened in MARCH3-depleted cells.  
(A) Gene array analysis of siM3-transfected human brain endothelial cells compared to 
sic-transfected cells (Table S2). Heat-map of up- (>1.25, red) and down-regulated 
(<1.25, blue) genes, from siM3/sic fold changes in three independent experiments. The 
repartition of significantly (p<0.05) up- and down-regulated sequences is shown (top 
diagram). Protein coding RNAs (in yellow, 67% of total gene) were then classified 
according to their fold change of expression (siM3/sic, bottom diagram). (B-C) Table 
includes two of the best down- (blue) and up-regulated (red) genes (symbol names), 
together with p-value and fold change. Samples used for gene array were further 
processed for RT-PCR to validate main hits. (D-E) mRNA (D) and protein (E) expression 
of indicated targets were monitored three days post-transfection by RT-PCR and 
western-blots, respectively. Graphs showed quantification of fold change in three 
independents experiments. (F) Confocal analysis of tight junction-associated protein 
ZO-1 in sic- or siM3-transfected endothelial cells. Zoom on cell borders is shown on the 
right panel, together with an inverted image as processed by Image J (Fiji). Scale bars: 
10 µm. All panels are representative of at least three independent experiments. T-test *, 
p<0.05; **, p<0.01; ***, p<0.001. 
 
Figure 4. MARCH3 impact on OCLN gene expression relies on FoxO. 
(A-B) Human brain endothelial cells were transfected with siM3 or sic duplexes, 
processed for western-blots three days later, as indicated. (B) Alternatively, cells were 
stained for FoxO1 (green) and analyzed by confocal microscopy. Nuclei were 
counterstained with DAPI (blue). Graph showed the percentage of FoxO1-positive 
nuclei. Scale bars: 10 µm. n>200 cells, T-test: *, p<0.05. (C) Cells were exposed to the 
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FoxO1 inhibitor (AS1708727, iFoxo, 100 nM, three days) or vehicle (dmso) and 
processed for RT-PCR. (D) Permeability assays were performed in non-stimulated (ctl), 
histamine- (Hista) or IL-8-challenged HUVECs pre-treated with dmso and iFoxo. All 
panels are representative of at least three independents experiments. ANOVA test *, 
p<0.05; ***, p<0.001. 
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